| Annual Financials | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 0 | 887 | 1,549 | 1,886 | 2,138 | 2,190 | 2,295 | 2,421 | 2,438 |
| Expenses | 0 | 639 | 1,065 | 1,294 | 1,507 | 1,519 | 1,609 | 1,704 | 1,705 |
| EBITDA | 0 | 248 | 484 | 592 | 631 | 671 | 686 | 717 | 734 |
| Operating Profit % | -5 % | 28 % | 31 % | 31 % | 29 % | 30 % | 30 % | 29 % | 29 % |
| Depreciation | 0 | 19 | 29 | 33 | 38 | 42 | 54 | 61 | 63 |
| Interest | 0 | 1 | 34 | 88 | 28 | 1 | 2 | 2 | 3 |
| Profit Before Tax | 0 | 228 | 421 | 471 | 565 | 629 | 631 | 654 | 667 |
| Tax | 0 | 33 | 108 | 119 | 146 | 162 | 160 | 169 | 164 |
| Net Profit | -0 | 196 | 313 | 352 | 419 | 467 | 471 | 486 | 496 |
| EPS in ₹ | -7.89 | 24.64 | 29.04 | 32.61 | 35.63 | 38.11 | 38.43 | 39.63 | 40.40 |
Alivus Life Sciences
Alivus Life Sciences
939.20
-7.55
(-0.80%)
Market Cap
11,609.90 Cr
EPS
39.63
PE Ratio
23.11
Dividend Yield
0.54 %
Industry
Healthcare52 Week High
1,251.00
52 Week Low
850.00
PB Ratio
4.06
Debt to Equity
0.01
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
Company News
View All News
Alivus Life Sciences Reports 2.2% Revenue Growth in Q1 FY26 with Strong Margin ExpansionAug 08, 2025
Alivus Life Sciences reported revenues of INR 602 crores for Q1 FY26, representing a 2.2% year-on-year growth. The company's non-GPL business grew 14.5% year-on-year, driven by successful new launches, while GPL business declined 22% due to inventory rationalization. Gross margins improved to 55.1%, up 400 basis points year-on-year, and EBITDA margins reached 30.1%, up 210 basis points. The company generated strong cash flows of INR 100 crores and maintains a net debt-free position with cash reserves of INR 660 crores. Both Dahej and Ankleshwar facilities received successful US FDA inspections with NAI classifications. The CDMO business remained subdued with validation batches for the fifth project commencing, expecting commercialization in H2. The company maintains guidance of high single-digit revenue growth for FY26 despite pricing pressures, with margins expected to remain in the 28-30% range. Capex guidance stands at INR 600 crores including carryover from previous year, with Solapur facility expected to begin operations in Q4.
Alivus Life Sciences Reports Growth in Q1 Financial PerformanceAug 01, 2025
Alivus Life Sciences reported quarterly results showing revenue of 6.1 billion rupees compared to 5.9 billion rupees in the previous year. The company's EBITDA increased to 1.7 billion rupees from 1.6 billion rupees year-over-year, with EBITDA margin improving to 28.64% from 27.1%. Net profit rose to 1.2 billion rupees from 1.1 billion rupees in the same period last year.
Alivus Life Sciences Receives USFDA No Action Indicated Classification for Gujarat API Facility
Jul 26, 2025
Jul 26, 2025Alivus Life Sciences Limited received an Establishment Inspection Report with a No Action Indicated (NAI) classification from the USFDA for its API manufacturing facility located in Dahej, Gujarat. The classification follows a USFDA inspection conducted from May 26 to May 30, 2025. The NAI classification indicates that the facility met regulatory standards during the inspection. The company was formerly known as Glenmark Life Sciences Limited.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,586.70 | #1 3,90,467.80 | 33.18 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 51.86 | |
5,689.50 | 1,56,546.80 | 65.50 | 9,712.00 | 18.67 | 2,191 | 26.74 | 36.39 | |
1,499.40 | 1,21,939.70 | 22.45 | 28,409.50 | 7.12 | 5,291 | 9.88 | 38.89 | |
3,561.00 | 1,19,525.40 | 59.72 | 11,539.40 | 6.99 | 1,911 | 19.91 | 42.61 | |
1,253.10 | 1,06,424.50 | #1 18.40 | 33,741.20 | 16.73 | 5,725 | 1.26 | 46.51 | |
2,482.90 | 1,04,263.50 | 54.18 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 44.66 | |
975.00 | 1,02,560.40 | 21.07 | 23,511.00 | 18.55 | 4,615 | 2.60 | 50.50 | |
1,919.80 | 89,672.20 | 23.72 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.16 | |
5,433.00 | 65,856.40 | 28.53 | 13,458.30 | 3.70 | 2,216 | 21.39 | 61.31 | |
29,740.00 | 64,162.30 | 43.54 | 6,684.70 | 9.64 | 1,414 | 11.55 | 33.28 |
Forecast
Actual
Growth Rate
Revenue Growth
5.49 %
Net Income Growth
3.12 %
Cash Flow Change
-5.32 %
ROE
-14.61 %
ROCE
-14.94 %
EBITDA Margin (Avg.)
-0.94 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 | 3,411 |
| Fixed Assets | 0 | 456 | 546 | 573 | 590 | 781 | 805 | 955 |
| Current Assets | 0 | 931 | 1,160 | 1,399 | 1,765 | 1,850 | 1,916 | 2,335 |
| Capital Work in Progress | 0 | 80 | 11 | 14 | 97 | 62 | 106 | 102 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 478 |
| Other Assets | 0 | 939 | 1,169 | 1,410 | 1,784 | 1,860 | 1,939 | 1,877 |
| Total Liabilities | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 | 3,411 |
| Current Liabilities | 2 | 1,380 | 1,308 | 1,221 | 384 | 497 | 439 | 470 |
| Non Current Liabilities | 0 | 7 | 16 | 23 | 33 | 67 | 79 | 124 |
| Total Equity | -1 | 88 | 402 | 753 | 2,054 | 2,138 | 2,332 | 2,817 |
| Reserve & Surplus | -1 | 86 | 400 | 751 | 2,030 | 2,114 | 2,308 | 2,793 |
| Share Capital | 0 | 2 | 2 | 2 | 25 | 25 | 25 | 25 |
Cash Flow
| Cash Flow | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 0 | 2 | 8 | 106 | 397 | -228 | 18 | -230 |
| Investing Activities | 0 | -9 | -51 | -69 | -122 | -147 | -117 | -616 |
| Operating Activities | -1 | 10 | 195 | 388 | 598 | 306 | 414 | 392 |
| Financing Activities | 1 | 1 | -137 | -214 | -79 | -388 | -279 | -6 |
Share Holding
| % Holding | Apr 2021 | Aug 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 100.00 % | 82.84 % | 82.84 % | 82.85 % | 82.85 % | 82.85 % | 82.85 % | 82.85 % | 82.85 % | 82.85 % | 82.85 % | 82.85 % | 82.85 % | 82.85 % | 75.00 % | 75.00 % | 74.99 % | 74.94 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.00 % | 0.00 % | 0.00 % | 4.38 % | 0.00 % | 5.01 % | 4.82 % | 7.85 % | 6.74 % | 6.57 % | 6.42 % |
| DIIs | 0.00 % | 1.34 % | 0.30 % | 0.32 % | 0.50 % | 0.71 % | 0.79 % | 0.09 % | 0.00 % | 0.58 % | 0.64 % | 0.59 % | 1.40 % | 1.57 % | 4.16 % | 4.86 % | 5.19 % | 5.61 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 7.99 % | 7.97 % | 7.72 % | 7.80 % | 8.14 % | 9.14 % | 9.77 % | 10.87 % | 10.02 % | 9.20 % | 9.20 % | 9.09 % | 9.13 % | 10.63 % | 10.99 % | 10.50 % | 10.34 % |
| Others | 0.00 % | 7.83 % | 8.89 % | 9.11 % | 8.86 % | 8.31 % | 7.21 % | 7.29 % | 6.28 % | 6.55 % | 2.92 % | 7.36 % | 1.64 % | 1.64 % | 2.36 % | 2.41 % | 2.74 % | 2.69 % |
| No of Share Holders | 7 | 3,73,362 | 2,80,300 | 2,53,726 | 2,38,578 | 2,33,538 | 2,32,203 | 2,25,730 | 2,22,866 | 2,08,267 | 1,98,764 | 1,85,531 | 1,56,183 | 1,49,396 | 1,43,960 | 1,46,840 | 1,41,977 | 1,38,500 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21 | 42 | 22.5 | 5 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.49 | 5.41 | 2.08 | 0.53 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 23 Nov 2021 |  Dividend | ₹ 10.50 /share | 22 Nov 2021 | 637.10 | 611.65 |
| 17 Sept 2022 | Dividend | ₹ 10.50 /share | 15 Sept 2022 | 489.00 | 418.95 |
| 24 Mar 2023 | Dividend | ₹ 21.00 /share | 24 Mar 2023 | 382.65 | 413.10 |
| 17 Oct 2023 | Dividend | ₹ 22.50 /share | 17 Oct 2023 | 624.60 | 667.90 |
| 25 Sept 2024 |  Annual General Meeting | NA | 25 Sept 2024 | 1,076.05 | 1,107.00 |
| 09 Oct 2024 |  Change Of Name | NA | 09 Oct 2024 | 1,203.25 | 1,203.25 |
| 24 Oct 2024 |  Quarterly Result Announcement | NA | 24 Oct 2024 | 1,173.20 | 1,073.35 |
| 23 Jan 2025 | Quarterly Result Announcement | NA | 23 Jan 2025 | 1,065.60 | 1,122.65 |
| 15 May 2025 | Quarterly Result Announcement | NA | 15 May 2025 | 1,118.90 | 1,180.60 |
| 01 Aug 2025 | Quarterly Result Announcement | NA | 01 Aug 2025 | 1,024.35 | 1,030.30 |
| 01 Sept 2025 | Dividend | ₹ 5.00 /share | 01 Sept 2025 | 1,180.60 | 944.80 |
| 08 Sept 2025 | Annual General Meeting | NA | 08 Sept 2025 | 931.75 | 921.85 |
Announcements
Announcement under Regulation 30 (LODR)-Credit Rating10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Change in ManagementSep 08, 2025
Sep 08, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 08, 2025
Sep 08, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 08, 2025
Sep 08, 2025Change In Corporate Office Address.Sep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 21, 2025
Aug 21, 2025Disclosure under Regulation 30A of LODRAug 20, 2025
Aug 20, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 15, 2025
Aug 15, 2025Business Responsibility & Sustainability Report For FY 2024-25Aug 12, 2025
Aug 12, 2025Reg. 34 (1) Annual Report.Aug 12, 2025
Aug 12, 2025Notice Of 14Th Annual General Meeting Of The Company For FY 2024-25 As Required Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 12, 2025
Aug 12, 2025 Intimation Of Record Date For DividendAug 11, 2025
Aug 11, 2025Intimation Of 14Th Annual General Meeting And Record DateAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 04, 2025
Aug 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 02, 2025
Aug 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 02, 2025
Aug 02, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 01, 2025
Aug 01, 2025Unaudited Financial Results For The First Quarter Ended June 30 2025Aug 01, 2025
Aug 01, 2025Board Meeting Outcome for Unaudited Financial Results For The First Quarter Ended June 30 2025Aug 01, 2025
Aug 01, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 26, 2025
Jul 26, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJul 24, 2025
Jul 24, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJul 24, 2025
Jul 24, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 24, 2025
Jul 24, 2025Closure of Trading WindowJul 24, 2025
Jul 24, 2025Board Meeting Intimation for Inter Alia To Consider And Approve The Unaudited Financial Results Of The Company For The Quarter Ended 30Th June 2025.Jul 24, 2025
Jul 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 24, 2025
Jun 24, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotJun 23, 2025
Jun 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 09, 2025
Jun 09, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 30, 2025
May 30, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 23, 2025
May 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 16, 2025
May 16, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 15, 2025
May 15, 2025Appointment Of Secretarial AuditorMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 15, 2025
May 15, 2025Corporate Action-Board to consider DividendMay 15, 2025
May 15, 2025Board Meeting Outcome for Audited Financial Results For The Fourth Quarter And Year Ended March 31 2025May 15, 2025
May 15, 2025Audited Financial Results For The Fourth Quarter And Year Ended March 31 2025May 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 08, 2025
May 08, 2025Closure of Trading WindowMay 08, 2025
May 08, 2025Board Meeting Intimation for To Consider And Approve The Audited Financial Results Of The Company For The Quarter And Year Ended 31St March 2025 And To Consider And Recommend Dividend If Any On Equity Shares For The Year Ended March 31 2025.May 08, 2025
May 08, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 08, 2025
May 08, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSApr 30, 2025
Apr 30, 2025Technical Indicators
RSI(14)
Neutral 46.66
ATR(14)
Volatile 32.65
STOCH(9,6)
Neutral 47.55
STOCH RSI(14)
Neutral 43.86
MACD(12,26)
Bullish 4.34
ADX(14)
Weak Trend 19.46
UO(9)
Bearish 48.71
ROC(12)
Downtrend And Accelerating -0.67
WillR(14)
Oversold -81.87
Mutual Fund Holdings
Old Bridge Focused Fund Direct - Growth 
Union Small Cap Fund Direct-Growth 
Motilal Oswal Quant Fund Direct-Growth 
Tata Small Cap Fund Direct - Growth 
Helios Mid Cap Fund Direct-Growth 
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
SBI Nifty Smallcap 250 Index Fund Direct - Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth 
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth 
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth 
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth 
Kotak Nifty Smallcap 250 Index Fund Direct-Growth 
Groww Nifty Smallcap 250 Index Fund Direct - Growth 
Axis Nifty 500 Index Fund Direct-Growth 
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
